Longitudinal Knowledge Assessment
Nina Karlin, MD, Chair
Dr. Karlin has been at Mayo Clinic Arizona for the past 14 years, where she is a general medical oncologist and Associate Professor of Medicine of the Mayo Clinic College of Medicine and Sciences. She is board certified in Internal Medicine and Medical Oncology and is an active participant in the Maintenance of Certification program. Previously, Dr. Karlin was an internist at Weed Army Community Hospital at Fort Irwin, CA and at Blanchfield Army Community Hospital at Fort Campbell, Kentucky.
Dr. Karlin currently serves on the Medical Oncology Longitudinal Approval Committee for American Board if Internal Medicine. She has served on the Lifelong Learning Committee, Addressing Disparities in Older Adults Working Group, and Ethics Committee of American Society for Clinical Oncology. Locally, she is a member of the Mortality Committee, and has previously served on the Space and Capital Committee, Humanities in Medicine committee and Pharmacy Therapeutics committee. She is core faculty and member of program evaluation committees for Hematology Oncology fellowship and Internal Medicine residency programs, and a member of the Hematology Oncology fellowship clinical competency committee. She has active research with the Division of Endocrinology in cancer and diabetes.
Dr. Karlin received a bachelor's degree in classics and biology from Brown University, Providence, Rhode Island and her medical degree from Dartmouth College, Hanover, New Hampshire. She completed her internal medicine training at William Beaumont Army Medical Center and hematology oncology fellowship at University of California ,Los Angeles Olive View Medical Center.
As of July 2022, Dr. Karlin reported no ongoing external relationships.
Deborah K. Armstrong, MD
Dr. Armstrong is Professor of Oncology and of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine. She is board certified in Internal Medicine and Medical Oncology.
Previously, Dr. Armstrong chaired the Oncologic Drugs Advisory Committee for the U.S. Food & Drug Administration. She was a principal investigator for the Gynecologic Oncology Group (now NRG Oncology), serving on Ovarian Cancer, Medical Oncology and Phase I Committees. In addition, she has participated as a scientific reviewer for National Cancer Institute (NCI), Department of Defense, National Comprehensive Cancer Network and for the Stand Up to Cancer Ovarian Cancer Dream Team award, among others. She is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee.
Dr. Armstrong is a member of the Board of Directors of the Society of Gynecologic Oncology. and co-Chairs the Ovarian Cancer Task Force for the NCI. She is a representative of Johns Hopkins to the National Cooperative Cancer Network serving as co-Chair of the ovarian cancer panel. Dr. Armstrong directs the gynecologic oncology clinical trials program at the Johns Hopkins Kimmel Cancer Center and the breast and ovarian cancer genetic counseling service that identifies patients at risk for cancer and recommends strategies for cancer screening and prevention.
She was awarded a Komen Foundation Fellowship, a Young Investigator Award from American Society of Clinical Oncology, a Career Development Award from the American Cancer Society, the Ladies Home Journal Breakthrough Achievement Award, the Rosalind Franklin Award for Excellence in Ovarian Cancer Research and the Johns Hopkins Department of Medicine Osler Housestaff Teaching Award.
Dr. Armstrong received a bachelor's degree in bacteriology from the University of California at Berkeley then attended the George Washington University School of Medicine and was elected to Alpha Omega Alpha. Dr. Armstrong trained in internal medicine at the University of Pittsburgh and served as Chief Medical Resident before completing medical oncology fellowship at the Johns Hopkins Oncology Center.
As of May 2023, Dr. Armstrong reported the following external relationships:
Funding for clinical trial expenses, salary support and staff, paid to Johns Hopkins University, from the following companies:
- AstraZeneca, for two ovarian cancer trials.
- Clovis Oncology, for two ovarian cancer trials.
- Eisai, for an ovarian cancer trial.
- Pfizer, for an ovarian cancer trial.
- Syndax, for an ovarian cancer trial.
Service on data and safety monitoring boards for the following company, with compensation for travel expenses and honoraria:
- AstraZeneca, data and safety monitoring board for a study on ovarian cancer, and safety monitoring board for a study of advanced endometrial cancer, member.
Work as an author or editor for the following company, with compensation as listed below:
- UpToDate®, receiving compensation as an editor for ovarian cancer topics.
Dr. Armstrong serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- National Comprehensive Cancer Network, Chair of Ovarian Cancer Committee, Chair of YIA Award Recipient Selection Committee, receiving honoraria.
Brian Boulmay, MD
Dr. Boulmay is a hematologist and medical oncologist at LSU Health New Orleans and Program Director for the Hematology/Oncology Fellowship at Louisiana State University. He is board certified in Internal Medicine, Hematology and Medical Oncology and his clinical interests are in head and neck, lung and other aerodigestive tumors.
Dr. Boulmay earned his medical degree from Louisiana State University. He completed his internship and residency in internal medicine as well as a fellowship in hematology/oncology at the University of Florida.
As of May 2023, Dr. Moulmay reported no ongoing external relationships.
Robert Dreicer, MD, MS, MACP, FASCO
Dr. Dreicer is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia (UVA) Cancer Center. He serves as Section Head of Medical Oncology and co-Director of the Paul Mellon Urologic Institute. He is a professor of medicine and urology at the UVA School of Medicine. He previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center.
Dr. Dreicer is board certified in Internal Medicine and Medical Oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer has published widely in genitourinary oncology and served as Principal Investigator of a large number of studies in genitourinary neoplasms. He served as co-Chair of National Cancer Institute Genitourinary Steering Committee from 2012-18 and is a member of the Editorial Board of New England Journal of Medicine's Journal Watch Hematology/Oncology and the American Board of Internal Medicine's Medical Oncology Exam Committee from 2010-16. In October of 2016 he was awarded Mastership in the American College of Physicians.
Dr. Dreicer received his undergraduate degree at Colorado State University in Aurora and his master's degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his medical degree from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin.
As of July 2022, Dr. Dreicer reported the following external relationships:
Service on data and safety monitoring boards for the following companies, with honoraria:
- Hinova
- Merck
Service on a research-related advisory board for the following companies, with honoraria:
- Astellas
- AstraZeneca
- Bayer
- Exelixis
- Myovant
- Pfizer
- Sanofi
- Veru
Industry-supported continuing medical education supported by the following, with honoraria:
- Bayer
- Sanofi
Dipti Patel-Donnelly, MD
Dr. Patel-Donnelly, a board certified internist, medical oncologist and hematologist, is a managing partner at Virginia Cancer Specialists, which is a large multi-disciplinary private practice in Northern Virginia. She has been the co-Director of the Fairfax Stem Cell Transplant Program since 2009. Focusing on a special interest in hematologic malignancies, brain tumors and stem cell transplant, Dr. Patel-Donnelly has become highly involved in local tumor boards and currently serves as Section Chief of Hematology/Oncology at Inova Fairfax Hospital and holds a Hematology/Oncology Faculty Clerkship appointment at Virginia Commonwealth University.
Dr. Patel-Donnelly holds memberships and appointments in multiple organizations. She is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. She is also a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology and the Medical Society of Virginia. Dr. Patel-Donnelly has received multiple awards and honors which include the Leukemia and Lymphoma Society’s “Relentless for a Cure” award, Harvard Partners in Excellence Award, Excellence in Teaching Awards, National Institutes of Health Research Fellowship, NASE Achievement Scholarship and Distinguished Honors and Independent Research in Biochemistry.
Dr. Patel-Donnelly has been consistently named as a Top Doctor in publications such as Northern Virginia Magazine and Washingtonian Magazine. Additionally, she has been listed as a Castle Connolly Mid-Atlantic Top Doctor and a Washington Post Super Doctor. She is a published author and has spoken both at local educational events and in news interviews.
Dr. Patel-Donnelly completed her fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Massachusetts General Hospital at Harvard Medical School. Dr. Patel-Donnelly received her medical degree and completed her internal medicine internship and residency from the Mount Sinai School of Medicine in New York, New York, and she is a magna cum laude graduate in biochemistry with honors and independent research from Binghamton University in Binghamton, New York.
As of October 2021, Dr. Patel-Donnelly reported the following external relationships:
Funding for clinical trial expenses, paid to Virginia Cancer Specialists, from the following companies:
- Dr. Patel-Donnelly receives funding from ADCT Therapeutics, Ariad Pharmaceuticals, Astellas, AstraZeneca, Boston Biomedical, Clovis, EMD Serono, Gilead Sciences, Incyte, and Roche, to support trials on solid tumors and hematologic malignancies.
Traditional, 10-Year MOC Exam
Pamela N. Munster, MD, Chair
Dr. Munster, who is board certified in Internal Medicine and Medical Oncology, is Professor in Residence at the University of California, San Francisco, where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Program Leader of Developmental Therapeutics. She is the co-Leader of the BRCA Center.
She served at Memorial Sloan Kettering Cancer Center as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute, Tampa, Florida. Dr. Munster led the group as the Scientific Director of Breast Research and co-Chair of the Phase I Program at Moffitt for six years prior to joining the University of California, San Francisco.
Her basic laboratory research interests are in the area of developing novel targeted therapy for the treatment of treatment resistant cancer and their integration into current treatment strategies. Dr. Munster's research interest involves basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing histone deacetylase inhibitors HDAC inhibitors reverse hormone therapy resistance in breast cancer and to reengage the immune defense. Dr. Munster's clinical research interests are in the area of early anti-tumor drug development with focus on drugs that target the mTOR, P13k pathways and the epigenetic regulation of immune response to therapy. In addition to her interest in drug development, Dr. Munster has a special interest in the germline cancer mutations.
Dr. Munster has published in numerous scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research. She serves as Chair of the American Board of Internal Medicine Medical Oncology Board Exam Committee.
Dr. Munster received her medical degree from the University of Bern, Switzerland, completed her residency in internal medicine at Indiana University Medical Center then moved to Memorial Sloan Kettering Cancer Center, New York, for her oncology and hematology fellowship.
As of May 2023, Dr. Munster reported the following external relationships:
Preclinical research, with funding provided to the University of California, San Francisco, from the following companies:
- Merck
Funding for clinical trial expenses, staff and salary support, paid to the University of California, San Francisco, from the following companies:
- Amgen
- Arch
- Arvinas
- AstraZeneca
- BlissBio
- Bristol-Myers Squibb
- Celgene
- Cleave Biosciences
- Clovis Oncology
- Corcept Therapeutics
- Cyteir
- Genentech
- GlaxoSmithKline
- InvestisBio
- JSI
- Medimmune
- Merck
- Nektar Therapeutics
- Novartis
- Roche
- Revolution Medicine
- Roche
- Sanofi
- Scorpoion
- Seagen
- Xynomics
Attendance at investigators’ meetings, with honoraria from the following companies:
- Janssen
- Sanofi
- Sensei
Service on data and safety monitoring boards for the following company with honoraria:
- OncoSec
Service on a research-related expert panel or advisory board for the following company, with honoraria:
- GlaxoSmithKline
Dr. Munster earns domestic and international royalties regarding a healthcare-related patent from Alessa. She also serves on the Board of Directors of Alessa, and has received compensation for honoraria and travel reimbursement. She is the medical advisor for two Phase I clinical trials.
Dr. Munster also reported receiving educational grants from the National Cancer Institute, the National Institutes of Health and the University of California, San Francisco to support fellows.
Hossein Borghaei, MD
Dr. Borghaei is the Chief of Thoracic Medical Oncology, Professor in the department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in Thoracic Medical Oncology. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with mung cancer.
In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the Principal Investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. The work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.
Dr. Borghaei earned his degree at Philadelphia College of Osteopathic Medicine and completed a residency at Graduate Hospital in Philadelphia.
As of August 2021, Dr. Borghaei reported the following external relationships:
Funding for clinical trial expenses and staff from the following companies:
- Bristol-Myers Squibb
- Eli Lily & Company
Service on data and safety monitoring boards for the following companies, with honoraria:
- Incyte, serving as a data and safety monitoring board chair.
- Takeda, serving on a data and safety monitoring board.
- University of Pennsylvania, serving on multiple data and safety monitoring boards regarding CAR-T Cells.
Service on a research-related advisory board for the following companies, with honoraria:
- Genetech
- AstraZeneca
- Amgen
- Rgenix
- Genmab
Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation honoraria:
- Bristol-Myers Squibb
- Merck
- Regeneron
- Mirati
- Daiichi Sankyo
- Boehringer Ingelheim
- EMD Serono
- AstraZeneca
- Beigene
Industry-supported continuing medical education supported by the following, with honoraria:
- Medscape
- Physicans Education Resource
Teaching in or developing continuing medical education with funding from the following companies, with honoraria:
- Daiichi Sankyo, regarding state of lung cancer treatment.
- Beigene, regarding use of immunotherapy in lung cancer.
Dr.Borghaei serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- GO2 Foundation for Lung Cancer, Scientific Advisory Board, without compensation.
Bartosz Chmielowski, MD, PhD
Dr. Chmielowski is an Associate Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California Los Angeles (UCLA).
He has been ABIM Board Certified in Medical Oncology and Hematology since 2008. Dr. Chmielowski has been a UCLA faculty member since 2008, and his both clinical and laboratory research concentrates on the development of new therapies for patients with melanoma, non-melanoma skin cancers and sarcoma. He has a special interest in the development of new immunotherapeutic agents and new combination immunotherapies not only in melanoma, but also in non-melanoma skin cancers and sarcoma including patients with gastrointestinal stromal tumors. In addition, he studies new molecularly targeted agents in both sarcoma and melanoma.
He graduated from the Medical School at Wroclaw, Poland. He moved to the United States to pursue research career in immunology at the Medical College of Georgia in Augusta, Georgia. He concentrated on studying T cell development in the thymus, especially the processes of positive and negative selection. His research resulted in a doctoral thesis.
He completed his residency in Internal Medicine at the Medical College of Georgia in Augusta, Georgia, and completed his fellowship in hematology-oncology at UCLA.
As of July 2022, Dr. Chmielowski reported the following external relationships:
Funding for clinical trial expenses, salary support and staff, paid to the University of California Los Angeles, from the following companies:
- Aeglea
- Array Biopharma
- Ascentage
- Advenchen
- Atreca
- Bristol-Myers Squibb
- Compugen
- Eli Lilly & Company
- EMD Serono
- Daiichi Sankyo
- Ideaya
- Idera
- Incyte
- Infinity Pharma
- Inspirna (Formerly Rgenix)
- InstilBio
- Iovance
- Karyopharm
- Kinnate
- Macrogenics
- Merck
- Novartis
- PACT Pharma
- PTC Therapeutics
- RAPT Therapeutics
- Replimune
- SARC
- SWOG
- Xencor
Service on a research-related advisory board for the following companies, with compensation for travel expenses and honoraria:
- Deciphera
- Instilbio
- Nektar
- Novarti
Work as an author or editor for the following company, with compensation as listed:
- Wolters Kluwer, receiving compensation as editor of The Editor of the Manual of Clinical Oncology.
Manish A. Shah, MD
Dr. Shah, the Bartlett Family Associate Professor of Gastrointestinal Oncology, is recognized as an excellent clinical and translational investigator focusing on drug development and advancing the care of gastrointestinal malignancies. Presently, his academic titles include Chief, Solid Tumor Oncology Service, Director, Gastrointestinal Oncology Program at Weill Cornell Medicine and co-Director, Center for Advanced Digestive Care, New York Presbyterian Hospital.
He has published over 100 peer-reviewed articles and has received numerous peer-reviewed funding awards. His research focuses on drug development and understanding mechanisms of resistance to therapy in Gastrointestinal Malignancies.
He received a bachelor's degree in educational studies in biomedical engineering from Johns Hopkins University, and his medical degree from the Harvard/Massachusetts Institute of Technology Health Sciences and Training program. His residency was completed in internal medicine at Duke Medical Center in Durham, North Carolina, and he completed his training in oncology at Memorial Sloan Kettering / Weill Cornell Medicine, where he was Chief Fellow.
As of June 2022, Dr. Shah reported the following external relationships:
Funding for clinical trial expenses, salary support and staff, paid to Weill Cornell Medicine from the following companies:
- Oncolys Biopharma, for a study of IIT study of novel oncolytic adenovirus + pembrolizumab, receiving funding for clinical trial expenses, salary support and staff.
- Bristol-Myers Squibb, receiving funding for clinical trial expenses, salary support and staff.
Lori J. Wirth, MD
Dr. Wirth is the Medical Director of the Head and Neck Oncology Program at Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. Before joining Mass General in 2008, Dr. Wirth was on staff at the Dana-Farber Cancer Institute. She is board certified in Medical Oncology.
Dr. Wirth is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. She currently serves as the Chairperson of the International Thyroid Oncology Program and sits on the National Comprehensive Cancer Network's Thyroid Carcinoma Guidelines Panel. She is also a member of the Dana-Farber/Harvard Cancer Center Scientific Review Committee. She has previously served on the Dana-Farber/Harvard Cancer Center Institutional Review Board and the National Cancer Institute's Head and Neck Cancer Steering Committee Recurrent/Metastatic Disease Task Force and has recently served on the American Joint Committee on Cancer's Endocrine Expert Panel.
Dr. Wirth received her bachelor's degree from Brown University and medical degree from Columbia University's College of Physicians and Surgeons. She completed her internal medicine residency at New York Presbyterian Medical Center, Columbia Presbyterian and completed a three-year fellowship in the Dana-Farber/Partners CancerCare Hematology/Oncology Program.
As of October 2021, Dr. Wirth reported the following external relationships:
Funding for clinical trial expenses and staff, paid to Massachusetts General Hospital, from the following companies:
- AstraZeneca, for a study of selumetinib in thyroid cancer and for a study of 5-azacytadine, durvalumab, tremilimumab for recurrent squamous cell carcinoma of the head and neck, receiving funding for clinical trial expenses and staff.
- Bayer, for an observational study of thyroid cancer, receiving funding for clinical research staff.
- Eisai, for a study of lenvatinib in thyroid cancer and in a combination Phase I trial, receiving funding for clinical trial expenses and staff.
- Merck, for a Phase Ib trial with pembrolizumab, receiving funding for clinical trial expenses and staff.
- Cue Biopharma, receiving funding for clinical trial expenses and staff.
- Checkmate, receiving funding for clinical trial expenses and staff.
- Tessa Therapeutics, receiving funding for clinical trial expenses and staff.
Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:
- PDS Biotechnology, honoraria
Service on a research-related expert panel or advisory board for the following companies, with honoraria:
- Eli Lilly & Company, serving on an advisory board.
Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation for travel expenses and/or honoraria:
- Eisai, for serving on an advisory board for lenvatinib in thyroid cancer, receiving reimbursement for travel expenses and honoraria.
- Merck, for serving on an advisory board for pembrolizumab in head and neck cancer, receiving reimbursement for travel expenses and honoraria.
- Genentech, for consulting on thyroid cancer, receiving honoraria.
- Ayala, receiving honoraria.
- Cue, receiving honoraria.
- Iovance, receiving honoraria.
Dr. Wirth serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- American Society of Clinical Oncology, Education Committee Member, receiving reimbursement for travel expenses.
- Translational Research in Oncology, Board Member, receiving reimbursement for travel expenses.